drugset
Drugs / Tobemstomig
last change Apr 2026 re-read 9 days ago

Tobemstomig

also known as RO7247669 · ANTI-PD1/ANTI-LAG3 BISPECIFIC ANTIBODY RO7247669 · PD1-LAG3 · PD1-LAG3 (RO-7247669) · PD1-LAG3 BSAB (RO-7247669) · RG-6139

Monoclonal antibody

Developed for
esophageal squamous cell carcinoma · melanoma · non-small cell lung carcinoma · breast cancer · hepatocellular carcinoma · liver cancer · metastatic melanoma · renal cell carcinoma
+1 more · urothelial carcinoma
Investigated by
Hoffmann-La Roche · Adagene Inc · Immune-Onc Therapeutics · NiKang Therapeutics, Inc. · Tempest Therapeutics

Trials 10

today NCT05908786 · Ph 1/2 NCT05852691 · Ph 2 NCT05805501 · Ph 2 NCT05645692 · Ph 2 NCT05775289 · Ph 2 NCT05419388 · Ph 2 NCT05116202 · Ph 1/2 NCT04785820 · Ph 2 NCT04524871 · Ph 1/2 NCT04140500 · Ph 1/2
20202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1/24 trials · 1 missed
Phase 1/2 NCT05908786 Dec 2023 → Aug 2025 hepatocellular carcinoma Hoffmann-La Roche Terminated No outcome recorded
Phase 1/2 NCT05116202 Feb 2022 → Sep 2023 melanoma Hoffmann-La Roche Completed Missed primary
Phase 1/2 NCT04524871 Nov 2020 → Jul 2027 expected liver cancer Hoffmann-La Roche Active not recruiting No outcome recorded
Phase 1/2 NCT04140500 Nov 2019 → Jun 2027 expected esophageal squamous cell carcinoma, metastatic melanoma, non-small cell lung carcinoma Hoffmann-La Roche Active not recruiting No outcome recorded
Phase 26 trials · 2 missed
Phase 2 NCT05852691 Jul 2023 → Oct 2026 expected breast cancer Hoffmann-La Roche Active not recruiting No outcome recorded
Phase 2 NCT05805501 Apr 2023 → Oct 2026 expected renal cell carcinoma Hoffmann-La Roche Active not recruiting No outcome recorded
Phase 2 NCT05645692 Apr 2023 → Dec 2026 expected urothelial carcinoma Hoffmann-La Roche Active not recruiting No outcome recorded
Phase 2 NCT05775289 Mar 2023 → Jun 2024 non-small cell lung carcinoma Hoffmann-La Roche Completed Missed primary
Phase 2 NCT05419388 Aug 2022 → May 2024 melanoma Hoffmann-La Roche Completed No outcome recorded
Phase 2 NCT04785820 Jun 2021 → Jan 2025 esophageal squamous cell carcinoma Hoffmann-La Roche Completed Missed primary

Evidence & citations 10 cited values

Every value below carries the sentence it was read from. 12 sources stand behind the page.

FieldValueCited text
Known as tobemstomig “tobemstomig (anti-PD-1/anti-LAG-3 bispecific antibody; n = 40)” PMID 40993242 ↗ Sep 2025
7

NCT04785820 ↗

NCT05805501 ↗

NCT05775289 ↗

NCT04524871 ↗

NCT05645692 ↗

NCT05908786 ↗

NCT05852691 ↗
Known as ANTI-PD1/ANTI-LAG3 BISPECIFIC ANTIBODY RO7247669 ChEMBL registry synonym — accepted as the source's own label CHEMBL5315001 ↗
Known as PD1-LAG3 ChEMBL registry synonym — accepted as the source's own label CHEMBL5315001 ↗
Known as PD1-LAG3 (RO-7247669) ChEMBL registry synonym — accepted as the source's own label CHEMBL5315001 ↗
Known as PD1-LAG3 BSAB (RO-7247669) ChEMBL registry synonym — accepted as the source's own label CHEMBL5315001 ↗
Known as RG-6139 ChEMBL registry synonym — accepted as the source's own label CHEMBL5315001 ↗
Known as RO7247669 ClinicalTrials.gov intervention name — accepted as the source's own label NCT05419388 ↗
2

NCT04140500 ↗

NCT05116202 ↗
Action Inhibit “an anti PD-1 (programmed death-1) and LAG-3 (Lymphocyte-activation gene 3) bispecific antibody” NCT04140500 ↗
Modality Monoclonal antibody — CHEMBL5315001 ↗
Route Intravenous “intravenous (IV) RO7247669” NCT04140500 ↗